EQUITY RESEARCH MEMO

PannonPharma

Generated 5/9/2026

Executive Summary

Conviction (model self-assessment)40/100

PannonPharma is a Hungarian pharmaceutical company founded in 2010, headquartered in Budapest, with its manufacturing facility in Pécsvárad. The company specializes in the development, manufacturing, and sale of generic drugs, over-the-counter (OTC) medicines, and dietary supplements. Its product portfolio covers treatments for respiratory conditions, skin infections, allergies, and general wellness, combining modern manufacturing techniques with a commitment to traditional quality. As a private entity, PannonPharma operates primarily in the Central and Eastern European generic drug market, a segment characterized by steady demand due to cost-conscious healthcare systems and aging populations. The company's focus on affordable generics and OTC products positions it to benefit from ongoing patent expirations and the shift towards self-medication. However, its private status and lack of disclosed financials or pipeline visibility limit external assessment of its growth trajectory and competitive standing.

Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)